35 completed, 27 recruiting, 25 unknown, 15 terminated. 71 Phase 2, 38 Phase 1, 16 Phase 3, 7 Not applicable, 2 Phase 4.
Follow Triple-negative Breast Cancer: new trials by email Literature Review of Triple-negative Breast Cancer trials Research Report on Triple-negative Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC) JS212 in combination with JS207, JS212 monotherapy, JS212 in combination with JS001 - Triple-negative Breast Cancer | Phase 2 | Not yet recruiting | Shanghai Junshi Bioscience Co., Ltd. | 184 | 2026-10-15 | 2026-10-15 |
| Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer LVB infiltration - Triple-negative Breast Cancer | Phase 2 | Not yet recruiting | Institut Jean-Godinot | 760 | 2026-10-01 | 2026-03-09 |
| A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors [68Ga]Ga-DWJ155 - Advanced Gastroesophageal Adenocarcinoma, Advanced Breast Cancer | Phase 1 | Recruiting | Novartis Pharmaceuticals | 66 | 2026-09-08 | 2026-10-13 |
| NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer Sacituzumab govitecan, Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA], SoC Chemotherapy - Breast Cancer, Triple-negative Breast Cancer | Phase 3 | Not yet recruiting | Women's Cancer Study Group GmbH | 765 | 2026-08-30 | 2026-08-05 |
| Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC Dual-target CAR-NK cells, Lymphodepleting, Supportive care - Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 60 | 2026-02-02 | 2026-04-06 |
| An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy Pegfilgrastim (Neulasta) - Triple-Negative Breast Cancer | Not applicable | Recruiting | Yonsei University | 40 | 2025-10-28 | 2026-04-20 |
| JS207 Combination Therapy in Triple-negative Breast Cancer JS207 in combination with 9MW2821, JS207 in combination with Albumin paclitaxel - Triple-negative Breast Cancer | Phase 2 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 80 | 2025-09-17 | 2026-04-15 |
| Triple Negative Breast Cancer and Celecoxib. Pilot Study Celecoxib (Celebrex), Placebo - Triple-Negative Breast Cancer | Phase 2 | Recruiting | Université de Sherbrooke | 30 | 2025-08-04 | 2025-08-05 |
| Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients Docetaxel plus cyclophosphamide, Epirubicin, cyclophosphamide plus paclitaxel - Triple-negative Breast Cancer | Phase 3 | Not yet recruiting | Fudan University | 1462 | 2025-02-01 | 2025-01-28 |
| Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC Pembrolizumab 25 mg/ml, Paclitaxel injection - Triple-negative Breast Cancer | Phase 2 | Recruiting | UNICANCER | 354 | 2024-12-27 | 2026-07-24 |
| Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC 6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1), 6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1) - Triple-negative Breast Cancer | Phase 2 | Recruiting | Henan Cancer Hospital | 64 | 2024-11-06 | 2025-12-05 |
| Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK INT230-6, neoadjuvant immuno-chemotherapy - Triple-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 2 | Recruiting | Swiss Cancer Institute | 61 | 2024-10-24 | 2026-10-23 |
| A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC. ATRA, Toripalimab - Triple-negative Breast Cancer | Not applicable | Recruiting | First Affiliated Hospital of Zhejiang University | 29 | 2024-10-10 | 2025-08-12 |
| Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors MNPR-101-PCTA-177Lu - Solid Tumor, Adult, Bladder Cancer | Phase 1 | Active not recruiting | Monopar Therapeutics | 12 | 2024-10-08 | 2026-09-03 |
| Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study Tislelizumab + Nab-Paclitaxel, Rankl inhibitor - Triple-negative Breast Cancer, Bone Metastases | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 20 | 2024-08-20 | 2024-11-26 |
| A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer BL-B01D1, PD-1 Monoclonal Antibody - Triple-negative Breast Cancer | Phase 2 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 52 | 2024-08-02 | 2026-07-23 |
| PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy., 9 cycles of Camrelizumab as adjuvant therapy. - Triple-negative Breast Cancer | Phase 3 | Recruiting | Guangdong Provincial People's Hospital | 310 | 2024-08-01 | 2024-11-04 |
| A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer 9MW2821, PD-1 inhibitior - Triple-Negative Breast Cancer | Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 160 | 2024-07-26 | 2025-01-10 |
| Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) Pembrolizumab, Sacituzumab tirumotecan, Capecitabine - Triple-Negative Breast Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1530 | 2024-06-24 | 2026-10-13 |
| A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02) BL-B01D1, Eribulin, Vinorelbine - Triple-Negative Breast Cancer | Phase 3 | Active not recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 418 | 2024-06-21 | 2026-07-23 |
Showing 20 of 125. Sign in to see all of them.
Triple Negative Breast Neoplasms (125) · Breast Neoplasms (37) · Carcinoma, Non-Small-Cell Lung (15) · Ovarian Neoplasms (11) · Carcinoma, Renal Cell (9) · Melanoma (8) · Pancreatic Neoplasms (8) · Squamous Cell Carcinoma of Head and Neck (8) · Stomach Neoplasms (8) · Colorectal Neoplasms (7) · Carcinoma, Transitional Cell (6) · Neoplasm Metastasis (6) · Small Cell Lung Carcinoma (6) · Uterine Cervical Neoplasms (6) · Carcinoma, Hepatocellular (5)
Skin and Connective Tissue Diseases (125) · Breast Diseases (124) · Neoplasms by Site (124) · Skin Diseases (124) · Neoplasms (121) · Breast Neoplasms (88) · Neoplasms by Histologic Type (22) · Female Urogenital Diseases (20) · Female Urogenital Diseases and Pregnancy Complications (20) · Urogenital Diseases (20) · Urogenital Neoplasms (20) · Lung Diseases (19) · Respiratory Tract Diseases (19) · Respiratory Tract Neoplasms (19) · Thoracic Neoplasms (19)
Carboplatin (17) · Paclitaxel (14) · 130-nm albumin-bound paclitaxel (13) · pembrolizumab (13) · Albumin-Bound Paclitaxel (9) · camrelizumab (9) · Capecitabine (8) · Cyclophosphamide (8) · Cisplatin (6) · Epirubicin (6) · apatinib (6) · atezolizumab (6) · Docetaxel (5) · Doxorubicin (4) · Gemcitabine (4)
Fudan University (15) · Hoffmann-La Roche (5) · Guangdong Provincial People's Hospital (3) · National Cancer Institute (NCI) (3) · Shanghai Junshi Bioscience Co., Ltd. (3) · University of Washington (3) · Alliance for Clinical Trials in Oncology (2) · Gilead Sciences (2) · Henan Cancer Hospital (2) · Monopar Therapeutics (2) · Novartis Pharmaceuticals (2) · Pfizer (2) · Priyanka Sharma (2) · Sichuan Baili Pharmaceutical Co., Ltd. (2) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2)
United States (53) · China (43) · France (13) · Italy (12) · Australia (11) · Canada (11) · Spain (10) · Germany (9) · United Kingdom (9) · Belgium (8) · South Korea (8) · Japan (7) · Brazil (6) · Taiwan (6) · Argentina (5)
Priyanka Sharma, MD (3) · Jennifer Specht (2) · Jian Zhang (2) · Jiong Wu (2) · Zhimin Shao, Professor (2) · Agustin Garcia (1) · Agustin Garcia, MD (1) · Alexander Philipovskiy, MD, PhD (1) · Alice Chen, M.D. (1) · Alvaro Moreno Aspitia, MD (1) · Ana Oaknin, MD (1) · Barbara Pistilli, MD (1)
PMID 16011702, PMID 16077072, PMID 17438091, PMID 17641361, PMID 18258986, PMID 19097774, PMID 19299237, PMID 19487376, PMID 20157582, PMID 20304629, PMID 20404251, PMID 20586616, PMID 21633166, PMID 21865043, PMID 22323820, PMID 24399079, PMID 24529560, PMID 25092775, PMID 25349301, PMID 25585328, PMID 25589624, PMID 26006067, PMID 26056183, PMID 26059540, PMID 26316884, PMID 26438237, PMID 27282289, PMID 27872127, PMID 28564564, PMID 29501363, PMID 29577076, PMID 29620997, PMID 29660596, PMID 29713086, PMID 29846104, PMID 29846122, PMID 29873695, PMID 29878040, PMID 30061361, PMID 30100160, PMID 30207593, PMID 30345906, PMID 30400780, PMID 30479698, PMID 30680712, PMID 31177991, PMID 31849532, PMID 32448335, PMID 32450725, PMID 32657611
2019 (5), 2016 (4), 2023 (2), P30CA015704 (2), P30CA072720 (2), 2014 (1), 2015 (1), 2017 (1), 2018 (1), N01CM00032 (1), P30CA044579 (1), P50CA098131 (1), U10CA037447 (1)